Collaboration – a competitor's tool: The story of Centocor, an entrepreneurial biotechnology company
- 22 July 2009
- journal article
- research article
- Published by Informa UK Limited in Business History
- Vol. 51 (4), 529-546
- https://doi.org/10.1080/00076790902998512
Abstract
Biotechnology companies have relied on alliances for survival and growth since their inception. This history of Centocor illustrates the pivotal role collaborations played for pioneers in the industry. Five years after its founding Centocor had become a competitive and profitable diagnostics company based on partnerships with research institutes and larger health care companies. In 1992, however, Centocor faced collapse, brought on by a departure from collaboration and going it alone in the development and marketing of the company's first therapeutic. What saved the company and enabled it to prosper in therapeutics was a reversion to the old strategy of collaboration.Keywords
This publication has 12 references indexed in Scilit:
- Shaping the Industrial CenturyPublished by Harvard University Press ,2005
- Biography of Barry S. CollerProceedings of the National Academy of Sciences of the United States of America, 2004
- Biotechnology financing dilemmas and the role of special purpose entitiesNature Biotechnology, 2004
- Corporate venturing: the origins of Unilever's pregnancy testBusiness History, 2004
- Patents and Innovation in Cancer Therapeutics: Lessons from CellProThe Milbank Quarterly, 2002
- Making Dollars out of DNA: The First Major Patent in Biotechnology and the Commercialization of Molecular Biology, 1974-1980Isis, 2001
- Perfect partneringNature Biotechnology, 2001
- Listen to the MusicPublished by Springer Science and Business Media LLC ,2000
- Science and InnovationPublished by Cambridge University Press (CUP) ,1995
- Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against EndotoxinNew England Journal of Medicine, 1991